Phase 2 Endometrial Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Women between 18 and 75 years of age
• People with locally advanced cervical cancer (of a specific cell type — squamous, adenocarcinoma, or adenosquamous) that has been confirmed by a tissue sample and has not yet been treated
• People who have at least one tumour area of a minimum size that has not previously been treated locally, as measured by standard imaging guidelines
• People who are largely able to carry out daily activities with little or no restriction (this is measured using a standard medical scale — confirm with trial site)
• People with a life expectancy of at least 6 months
• People whose treating doctor considers them suitable for a standard combined chemotherapy and radiation treatment
• People with no significant active bleeding
• People whose blood test results show white blood cell and platelet counts above certain minimum levels
• People with no history of other cancers
• Women who could potentially become pregnant must have a negative blood pregnancy test and use reliable contraception throughout the trial
• People who have given written agreement to take part before any trial-related procedures begin

Who may not be able to join:

• People whose cancer has come back or spread to other parts of the body at the time of screening
• People with an active autoimmune disease that requires ongoing treatment, or any long-term condition requiring high doses of steroid or immune-suppressing medication
• People who have taken steroid medications above a certain dose, or other immune-suppressing drugs, within the 14 days before the first trial dose, or who are expected to need them during the trial
• People who have received a live vaccine within 30 days before the first dose, or who plan to during the trial
• People who have had an organ transplant, or who have a known HIV infection
• People with active hepatitis B or hepatitis C infections above certain levels, or who have both infections at the same time
• People who have previously been treated with certain types of immune checkpoint or immune-stimulating drugs (such as drugs targeting PD-1, PD-L1, CTLA-4, or similar pathways)
• People with a known serious allergic reaction to monoclonal antibodies, fusion proteins, or ingredients in the trial medicines
• People who have had another cancer in the past 5 years, with some exceptions for certain skin cancers or early-stage cancers considered fully treated (confirm with trial site)
• People with a serious non-surgical health condition or an active infection
• People with more than mild nerve damage affecting the hands or feet
• People whose blood tests show that bone marrow, liver, or kidney function falls below the levels required for the trial
• People with brain metastases (cancer that has spread to the brain) that are causing symptoms
• People with significant heart problems, including irregular heart rhythms, reduced blood supply to the heart, serious heart rhythm blockages, heart failure, or severe heart valve disease
• People with severe bone marrow failure
• People with an uncontrolled mental health condition
• Women who are pregnant or currently breastfeeding
• People the trial doctor considers unsuitable for participation for any reason
• People who are currently taking part in another interventional clinical trial

Important: Always verify eligibility with the trial site directly before applying.